Skip to NavigationSkip to content

Pfizer's Revatio flops in Phase 3 trial

Published on 01/07/19 at 10:00am

American multinational Pfizer has said that Revatio (Sildenafil Citrate) in combination with nitric oxide, has failed to meet its primary endpoint in a Phase 3 trial.

Pfizer’s Revatio combination therapy has flopped in a late-stage trial testing the drug’s effectiveness in treating new-born babies with persistent pulmonary hypertension.

The combination of inhaled nitric oxide and intravenously administered Revatio did not result in a reduction in the rate of treatment failure of inhaled nitric oxide, or in the amount of time new-born babies spent being treated with inhaled nitric oxide, compared to nitric oxide alone.

The second part of the trial is still ongoing as trial administrators will follow-up participants at 12 and 24 months after the end of the initial treatment to evaluate the developmental progress.

Revatio bares similarities to Pfizer’s erectile dysfunction drug Viagra (sildenafil) which was first developed to treat adults with high blood pressure in the lungs.

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches